pharmaphorum6d
ASCO22: Enhertu aces key HER2-low test in breast cancer
In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO ... for HER2+ metastatic gastric cancer, and recent ...
pharmaphorum1y
ASCO: Enhertu data sets up tumour-agnostic label bid
AstraZeneca and Daiichi Sankyo’s Enhertu is already gathering momentum as a treatment for HER2-positive and HER2-low breast, gastric, and lung cancer, but new data could be used to seek approval ...
ascopubs.org1mon
Effects of neighborhood deprivation index on survival in gastric cancers.
Effect of SHR-1701 on chemotherapy (chemo)-induced myelosuppression: Data from a phase 3 study in HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA). This is an ASCO Meeting ...
ascopubs.org1mon
A liquid biopsy analysis of exosomal miRNA to detect lymph node metastasis in early gastric cancer.
Relationship in gene amplification between ERBB2 and other oncogenes: Implications for the therapeutic efficacy of trastuzumab (Tmab)-based chemotherapy (CTx) in HER2 positive gastric cancer. This is ...
Nasdaq1mon
ALX Oncology Presents Positive Evorpacept Data at 2025 ASCO Gastrointestinal Cancers Symposium, Highlighting Strong Efficacy in HER2-Positive Cancer
ALX Oncology announced promising results from the ASPEN-06 Phase 2 clinical trial of its CD47-blocker, evorpacept, at the 2025 ASCO Gastrointestinal ... with HER2-positive advanced gastric and ...